SPIRou: A NIR Spectropolarimeter/High-Precision Velocimeter for the CFHT

International audienceSPIRou is a near-infrared (nIR) spectropolarimeter/velocimeter for the Canada-France-Hawaii Telescope (CFHT) that will focus on two forefront science topics, (i) the quest for habitable Earthlike planets around nearby M stars and (ii) the study of low-mass star/planet formation in the presence of magnetic fields. SPIRou will also efficiently tackle many key programs beyond these two main goals, from weather patterns on brown dwarfs to solar system planet and exoplanet atmospheres. SPIRou will cover a wide spectral domain in a single exposure (0.98-2.44 μm) at a resolving power of 70 K, yielding unpolarized and polarized spectra of low-mass stars with a 15% average throughput at a radial velocity (RV) precision of 1 m s-1. It consists of a Cassegrain unit mounted at the Cassegrain focus of CFHT and featuring an achromatic polarimeter, coupled to a cryogenic spectrograph cooled down at 80 K through a fluoride fiber link. SPIRou is currently integrated at IRAP/OMP and will be mounted at CFHT in 2018 Q1 for a first light scheduled in early 2018. Science operation is predicted to begin in 2018 S2, allowing many fruitful synergies with major ground and space instruments such as the JWST, TESS, ALMA, and later-on PLATO and the ELT

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials.

We investigated the prognostic impact and clinical utility of serum free light chains (sFLC) and serum heavy-light chains (sHLC) in patients with multiple myeloma treated according to the GEM2005MENOS65, GEM2005MAS65, and GEM2010MAS65 PETHEMA/GEM phase III clinical trials. Serum samples collected at diagnosis were retrospectively analyzed for sFLC (n = 623) and sHLC (n = 183). After induction or autologous transplantation, 309 and 89 samples respectively were available for sFLC and sHLC assays. At diagnosis, a highly abnormal (HA) sFLC ratio (sFLCr) (32) was not associated with higher risk of progression. After therapy, persistence of involved-sFLC levels >100 mg/L implied worse survival (overall survival [OS], P = 0.03; progression-free survival [PFS], P = 0.007). Among patients that achieved a complete response, sFLCr normalization did not necessarily indicate a higher quality response. We conducted sHLC investigations for IgG and IgA MM. Absolute sHLC values were correlated with monoclonal protein levels measured with serum protein electrophoresis. At diagnosis, HA-sHLCrs (73) showed a higher risk of progression (P = 0.006). Additionally, involved-sHLC levels >5 g/L after treatment were associated with shorter survival (OS, P = 0.001; PFS, P = 0.018). The HA-sHLCr could have prognostic value at diagnosis; absolute values of involved-sFLC >100 mg/L and involved-sHLC >5 g/L could have prognostic value after treatment